DARZALEX® was studied as a combination therapy and as a monotherapy.
Monday through Friday,
8:00 am to 8:00 pm ET
For relapsed multiple myeloma,
DARZALEX® is a prescription medicine used to treat multiple myeloma:
It is not known if DARZALEX® is safe and effective in children.
DARZALEX® is not chemotherapy. DARZALEX® is a monoclonal antibody that works in several ways. One way this monoclonal antibody works is by attaching itself to multiple myeloma cells in your body and directly killing them, and/or allowing your immune system to destroy them.
DARZALEX® targets and attaches to a protein called CD38, which is present on the surface of certain types of cells (eg, red blood cells) and is also present in high numbers on multiple myeloma cells. Since DARZALEX® targets the CD38 protein, it may also affect other cells with this protein on their surface.
*Please note that dates provided are recommendations for infusion visits only. Your doctor is likely to schedule additional follow-up/care visits and may alter the dates for your infusions depending on your availability and office availability.
Please contact the center to confirm hours of operation.
Would you like to clear your old dosing schedule and create a new one?
Please select the view mode for your dosing calendar.
Want a PDF of this treatment schedule?
Learn what you can expect before treatment with DARZALEX®.
Learn from patients on DARZALEX® and their caregivers about their experiences.
Learn about some useful tips to help you prepare for your infusion and feel comfortable during your appointments.
Janssen CarePath provides ongoing support, education, and resources during your treatment with DARZALEX®.